in the invention , the minimum inhibitory concentrations of human - originated egf domain proteins against different gram - negative bacteria are detected with the in vitro antibacterial activity . it has been shown that the human - originated egf domain proteins have an obvious inhibitory effect on the gram - negative bacteria , so as to develop a novel class of medicaments for treating gram - negative bacteria infection . it has been demonstrated by silver staining that the human - originated egf domain proteins have the effect on hydrolyzing and eliminating the endotoxin , which facilitates the development of a novel class of medicaments for treating endotoxemia . the amino acid sequences of the human - originated egf domain proteins are the one described in seq id no : 1 in the sequence listing , or those having homology of over 50 % to the amino acid sequence described in seq id no : 1 .